316 related articles for article (PubMed ID: 33538941)
21. Screening of hub genes associated with prognosis in non-small cell lung cancer by integrated bioinformatics analysis.
Zeng Y; Li N; Chen R; Liu W; Chen T; Zhu J; Zeng M; Cheng J; Huang J
Transl Cancer Res; 2020 Nov; 9(11):7149-7164. PubMed ID: 35117319
[TBL] [Abstract][Full Text] [Related]
22. Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer patients using microarray data.
Ma GF; Zhang RF; Ying KJ; Wang D
Eur Rev Med Pharmacol Sci; 2015 Feb; 19(4):578-85. PubMed ID: 25753874
[TBL] [Abstract][Full Text] [Related]
23. The Role of CEP55 Expression in Tumor Immune Response and Prognosis of Patients with Non-small Cell lung Cancer.
Fan H; Zhang J; Zou B; He Z
Arch Iran Med; 2022 Jul; 25(7):432-442. PubMed ID: 36404510
[TBL] [Abstract][Full Text] [Related]
24. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
Shen Q; Xu Z; Xu S
Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
[TBL] [Abstract][Full Text] [Related]
25. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
26. Identification of the Hub Genes Associated with the Prognosis of Ovarian Cancer Patients via Integrated Bioinformatics Analysis and Experimental Validation.
Zhao Y; Pi J; Liu L; Yan W; Ma S; Hong L
Cancer Manag Res; 2021; 13():707-721. PubMed ID: 33542655
[TBL] [Abstract][Full Text] [Related]
27. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
[TBL] [Abstract][Full Text] [Related]
28. GOLM1 and FAM49B: Potential Biomarkers in HNSCC Based on Bioinformatics and Immunohistochemical Analysis.
Xi Y; Zhang T; Sun W; Liang R; Ganesh S; Chen H
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499755
[TBL] [Abstract][Full Text] [Related]
29. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
30. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
31. Construction of a circular RNA-microRNA-messenger RNA regulatory network of hsa_circ_0043256 in lung cancer by integrated analysis.
Li Y; Shi R; Zhu G; Chen C; Huang H; Gao M; Xu S; Cao P; Zhang Z; Wu D; Li X; Liu H; Chen J
Thorac Cancer; 2022 Jan; 13(1):61-75. PubMed ID: 34806315
[TBL] [Abstract][Full Text] [Related]
32. Identification of six candidate genes for endometrial carcinoma by bioinformatics analysis.
Zhu Y; Shi L; Chen P; Zhang Y; Zhu T
World J Surg Oncol; 2020 Jul; 18(1):161. PubMed ID: 32641130
[TBL] [Abstract][Full Text] [Related]
33. Survival-based bioinformatics analysis to identify hub genes and key pathways in non-small cell lung cancer.
Liu C; Chen Y; Deng Y; Dong Y; Jiang J; Chen S; Kang W; Deng J; Sun H
Transl Cancer Res; 2019 Aug; 8(4):1188-1198. PubMed ID: 35116861
[TBL] [Abstract][Full Text] [Related]
34. Integrated bioinformatics analysis reveals novel key biomarkers and potential candidate small molecule drugs in gastric cancer.
Wu Q; Zhang B; Wang Z; Hu X; Sun Y; Xu R; Chen X; Wang Q; Ju F; Ren S; Zhang C; Qi F; Ma Q; Xue Q; Zhou YL
Pathol Res Pract; 2019 May; 215(5):1038-1048. PubMed ID: 30975489
[TBL] [Abstract][Full Text] [Related]
35. FIGNL1 is a potential biomarker of cisplatin resistance in non-small cell lung cancer.
Meng C; Yang Y; Ren P; Ju Q; Jin X; Long Q; Chen X; Wang X; Li F
Int J Biol Markers; 2022 Sep; 37(3):260-269. PubMed ID: 35791674
[TBL] [Abstract][Full Text] [Related]
36.
Cheng C; Wu X; Shen Y; Li Q
Cancer Manag Res; 2020; 12():13241-13257. PubMed ID: 33380832
[TBL] [Abstract][Full Text] [Related]
37. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
38. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis.
Wu Q; Zhang B; Sun Y; Xu R; Hu X; Ren S; Ma Q; Chen C; Shu J; Qi F; He T; Wang W; Wang Z
Onco Targets Ther; 2019; 12():3545-3563. PubMed ID: 31190860
[No Abstract] [Full Text] [Related]
40. Identifying the hub genes in non-small cell lung cancer by integrated bioinformatics methods and analyzing the prognostic values.
Wang T; Chen X; Jing F; Li Z; Tan H; Luo Y; Shi H
Pathol Res Pract; 2021 Dec; 228():153654. PubMed ID: 34749208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
